Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session - Non-metastatic NSCLC and other thoracic malignancies

LBA65 - First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743

Date

17 Sep 2021

Session

Proffered Paper session - Non-metastatic NSCLC and other thoracic malignancies

Presenters

Solange Peters

Citation

Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741

Authors

S. Peters1, A. Scherpereel2, R. Cornelissen3, Y. Oulkhouir4, L. Greillier5, M.A. Kaplan6, T. Talbot7, I. Monnet8, S. Hiret9, P. Baas10, A.K. Nowak11, N. Fujimoto12, A.S. Tsao13, A.S. Mansfield14, S. Popat15, X. Zhang16, N. Hu17, D. Balli18, J. Sanzari19, G. Zalcman20

Author affiliations

  • 1 Oncology Department, Lausanne University Hospital, 1011 - Lausanne/CH
  • 2 Pulmonary And Thoracic Oncology, University of Lille, CHU Lille, INSERM U1189, OncoThAI, 59037 - Lille/FR
  • 3 Pulmonary Medicine, Erasmus MC Cancer Institute, 3015 GD - Rotterdam/NL
  • 4 Pulmonary And Thoracic Oncology Department, Hôpital Côte de Nacre CHU Caen, 14000 - Caen/FR
  • 5 Multidisciplinary Oncology And Therapeutic Innovations Department, Aix Marseille University, APHM, INSERM, CNRS, CRCM, Hôpital Nord, 13915 - Marseille/FR
  • 6 Medical Oncology, Medical School, Dicle University, 21280 - Diyarbakir/TR
  • 7 The Sunrise Centre, Royal Cornwall Hospitals NHS Trust, TR1 3LJ - Truro/GB
  • 8 Department Of Pulmonology, Centre Hospitalier Intercommunal de Creteil, 94000 - Créteil/FR
  • 9 Medical Oncology, Institut de Cancérologie de l'Ouest, Site René Gauducheau, 44805 - Saint-Herblain Cedex/FR
  • 10 Department Of Thoracic Oncology, Netherlands Cancer Institute and Leiden University Medical Center, 1066 CX - Amsterdam/NL
  • 11 Medical School And Department Of Medical Oncology, University of Western Australia and Sir Charles Gairdner Hospital, 6009 - Perth/AU
  • 12 Department Of Medical Oncology, Okayama Rosai Hospital, 7028055 - Okayama/JP
  • 13 Department Of Thoracic/head And Neck Medical Oncology, MD Anderson Cancer Center, 77030 - Houston/US
  • 14 Division Of Medical Oncology, Mayo Clinic, 55905 - Rochester/US
  • 15 Lung Unit, Royal Marsden Hospital and The Institute of Cancer Research, SW7 3RP - London/GB
  • 16 Oncology Clinical Development, Bristol Myers Squibb, 08648 - Princeton/US
  • 17 Global Biometrics And Data Sciences, Bristol Myers Squibb, 08648 - Princeton/US
  • 18 Translational Bioinformatics – Informatics And Predictive Sciences, Bristol Myers Squibb, 08648 - Princeton/US
  • 19 Ww Medical Oncology, Bristol Myers Squibb, 08648 - Princeton/US
  • 20 Thoracic Oncology Department, Bichat-Claude Bernard University Hospital, AP-HP, Université de Paris, 75018 - Paris/FR
More

Resources

Login to access the resources on OncologyPRO.

Abstract LBA65

Background

In the randomized phase 3 CheckMate 743 study (NCT02899299), NIVO + IPI significantly prolonged overall survival (OS) vs chemo in pts with unresectable MPM. Here we report updated efficacy and safety with a 3-y minimum follow-up (f/u), as well as novel biomarker analyses.

Methods

Pts with untreated MPM, stratified by histology (epithelioid vs non-epithelioid) and sex, were randomized 1:1 to NIVO 3 mg/kg Q2W + IPI 1 mg/kg Q6W (≤ 2 y) or to chemo Q3W (6 cycles). The primary endpoint was OS; safety and biomarker assessments were prespecified exploratory endpoints. OS association with a 4-gene inflammatory gene expression signature (CD8A, PD-L1, STAT-1, LAG-3) was estimated by RNA sequencing and categorized as high vs low relative to median score. Lung immune prognostic index (LIPI) score was based on baseline (BL) derived neutrophil-to-lymphocyte ratio and lactate dehydrogenase levels.

Results

With a minimum f/u of 35.5 mo (database lock [DBL] 7 May 2021), NIVO + IPI continued to provide OS benefit vs chemo (HR 0.75, 95% CI 0.63–0.90; Table). In exploratory biomarker analyses, median OS was longer for pts with high vs low inflammatory gene signature score (21.8 vs 16.8 mo) in the NIVO + IPI arm; this signature score was not associated with prolonged OS for chemo. OS showed a trend favoring NIVO + IPI vs chemo across good, intermediate, and poor BL LIPI subgroups; HR (95% CI), 0.78 (0.60–1.01), 0.76 (0.57–1.01), and 0.83 (0.44–1.57), respectively. Grade 3–4 treatment-related adverse events occurred in 30.7% (NIVO + IPI) and 32.0% (chemo) of pts; no increase was reported from the previous DBL. Table: LBA65

Efficacy outcomes with NIVO + IPI vs chemo

NIVO + IPI (n = 303) Chemo (n = 302)
OS
Median (95% CI), mo 18.1 (16.8–21.0) 14.1 (12.4–16.3)
HR vs chemo (95% CI) 0.75 (0.63–0.90)
3-y OS rate (95% CI), % 23.2 (18.4–28.2) 15.4 (11.5–19.9)
3-y PFS a rate (95% CI), % 13.6 (9.4–18.6) 0.8 (0.1–3.9)
ORR a (95% CI), % 39.6 (34.1–45.4) 44.0 (38.4–49.8)
DOR a,b
Median (95% CI), mo 11.6 (8.2–16.8) 6.7 (5.6–7.1)
3-y DOR rate, % 28 0

aPer blinded independent central review; bCalculated in patients with a response (NIVO + IPI, n = 120; chemo, n = 133). DOR, duration of response; ORR, objective response rate; PFS, progression-free survival.

Conclusions

With a 3-y minimum f/u, NIVO + IPI continued to provide survival benefit vs chemo in pts with unresectable MPM despite pts being off therapy for 1 y; no new safety signals were observed. Exploratory analyses suggest that a high inflammatory gene signature score may correlate with improved survival benefit with NIVO + IPI.

Clinical trial identification

NCT02899299; 14 September 2016.

Editorial acknowledgement

All authors contributed to and approved the presentation; writing and editorial assistance were provided by Nick Patterson, PhD, of Caudex, London, UK, funded by Bristol Myers Squibb.

Legal entity responsible for the study

Bristol Myers Squibb (Princeton, NJ) and Ono Pharmaceutical Company Ltd. (Osaka, Japan).

Funding

Bristol Myers Squibb.

Disclosure

S. Peters: Financial Interests, Institutional, Advisory Role, Received honoraria (all fees to institution): AbbVie; Financial Interests, Institutional, Advisory Role, Received honoraria (all fees to institution): Amgen; Financial Interests, Institutional, Research Grant, Received honoraria (all fees to institution): Amgen; Financial Interests, Institutional, Advisory Role, Received honoraria (all fees to institution): AstraZeneca; Financial Interests, Institutional, Speaker’s Bureau, Received honoraria (all fees to institution): AstraZeneca; Financial Interests, Institutional, Research Grant, Received honoraria (all fees to institution): AstraZeneca; Financial Interests, Institutional, Advisory Role, Received honoraria (all fees to institution): Bayer; Financial Interests, Institutional, Advisory Role, Received honoraria (all fees to institution): Beigene; Financial Interests, Institutional, Advisory Role, Received honoraria (all fees to institution): Biocartis; Financial Interests, Institutional, Research Grant, Received honoraria (all fees to institution): Biodesiex; Financial Interests, Institutional, Advisory Role, Received honoraria (all fees to institution): Boehringer Ingelheim; Financial Interests, Institutional, Speaker’s Bureau, Received honoraria (all fees to institution): Boehringer Ingelheim; Financial Interests, Institutional, Research Grant, Received honoraria (all fees to institution): Boehringer Ingelheim; Financial Interests, Institutional, Advisory Role, Received honoraria (all fees to institution): Bristol Myers Squibb; Financial Interests, Institutional, Speaker’s Bureau, Received honoraria (all fees to institution): Bristol Myers Squibb; Financial Interests, Institutional, Research Grant, Received honoraria (all fees to institution): Bristol Myers Squibb; Financial Interests, Institutional, Advisory Role, Received honoraria (all fees to institution): Clovis; Financial Interests, Institutional, Research Grant, Received honoraria (all fees to institution): Clovis; Financial Interests, Institutional, Advisory Role, Received honoraria (all fees to institution): Daiichi Sankyo; Financial Interests, Institutional, Advisory Role, Received honoraria (all fees to institution): Debiopharm; Financial Interests, Institutional, Advisory Role, Received honoraria (all fees to institution): ecancer; Financial Interests, Institutional, Speaker’s Bureau, Received honoraria (all fees to institution): ecancer; Financial Interests, Institutional, Advisory Role, Received honoraria (all fees to institution): Eli Lilly; Financial Interests, Institutional, Speaker’s Bureau, Received honoraria (all fees to institution): Eli Lilly; Financial Interests, Institutional, Advisory Role, Received honoraria (all fees to institution): Foundation Medicine; Financial Interests, Institutional, Research Grant, Received honoraria (all fees to institution): GlaxoSmithKline; Financial Interests, Institutional, Advisory Role, Received honoraria (all fees to institution): Illumina; Financial Interests, Institutional, Speaker’s Bureau, Received honoraria (all fees to institution): Illumina; Financial Interests, Institutional, Research Grant, Received honoraria (all fees to institution): Illumina; Financial Interests, Institutional, Advisory Role, Received honoraria (all fees to institution): Imedex; Financial Interests, Institutional, Advisory Role, Received honoraria (all fees to institution): IQVIA; Financial Interests, Institutional, Advisory Role, Received honoraria (all fees to institution): Incyte; Financial Interests, Institutional, Advisory Role, Received honoraria (all fees to institution): Janssen; Financial Interests, Institutional, Research Grant, Received honoraria (all fees to institution): Lilly; Financial Interests, Institutional, Advisory Role, Received honoraria (all fees to institution): Medscape; Financial Interests, Institutional, Speaker’s Bureau, Received honoraria (all fees to institution): Medscape; Financial Interests, Institutional, Advisory Role, Received honoraria (all fees to institution): Merck Sharp & Dohme; Financial Interests, Institutional, Speaker’s Bureau, Received honoraria (all fees to institution): Merck Sharp & Dohme; Financial Interests, Institutional, Research Grant, Received honoraria (all fees to institution): Merck Sharp & Dohme; Financial Interests, Institutional, Advisory Role, Received honoraria (all fees to institution): Merck Serono; Financial Interests, Institutional, Research Grant, Received honoraria (all fees to institution): Merck Serono; Financial Interests, Institutional, Advisory Role, Received honoraria (all fees to institution): Merrimack; Financial Interests, Institutional, Research Grant, Received honoraria (all fees to institution): Mirati; Financial Interests, Institutional, Advisory Role, Received honoraria (all fees to institution): Novartis; Financial Interests, Institutional, Speaker’s Bureau, Received honoraria (all fees to institution): Novartis; Financial Interests, Institutional, Research Grant, Received honoraria (all fees to institution): Novartis; Financial Interests, Institutional, Advisory Role, Received honoraria (all fees to institution): PharmaMar; Financial Interests, Institutional, Advisory Role, Received honoraria (all fees to institution): Phosplatin Therapeutics; Financial Interests, Institutional, Research Grant, Received honoraria (all fees to institution): Phosplatin Therapeutics; Financial Interests, Institutional, Advisory Role, Received honoraria (all fees to institution): PER; Financial Interests, Institutional, Speaker’s Bureau, Received honoraria (all fees to institution): PER; Financial Interests, Institutional, Advisory Role, Received honoraria (all fees to institution): Pfizer; Financial Interests, Institutional, Speaker’s Bureau, Received honoraria (all fees to institution): Pfizer; Financial Interests, Institutional, Research Grant, Received honoraria (all fees to institution): Pfizer; Financial Interests, Institutional, Advisory Role, Received honoraria (all fees to institution): PRIME; Financial Interests, Institutional, Speaker’s Bureau, Received honoraria (all fees to institution): PRIME; Financial Interests, Institutional, Advisory Role, Received honoraria (all fees to institution): Regeneron; Financial Interests, Institutional, Advisory Role, Received honoraria (all fees to institution): Roche/Genentech; Financial Interests, Institutional, Speaker’s Bureau, Received honoraria (all fees to institution): Roche/Genentech; Financial Interests, Institutional, Research Grant, Received honoraria (all fees to institution): Roche/Genentech; Financial Interests, Institutional, Advisory Role, Received honoraria (all fees to institution): RTP; Financial Interests, Institutional, Speaker’s Bureau, Received honoraria (all fees to institution): RTP; Financial Interests, Institutional, Advisory Role, Received honoraria (all fees to institution): Sanofi; Financial Interests, Institutional, Speaker’s Bureau, Received honoraria (all fees to institution): Sanofi; Financial Interests, Institutional, Advisory Role, Received honoraria (all fees to institution): Seattle Genetics; Financial Interests, Institutional, Advisory Role, Received honoraria (all fees to institution): Takeda; Financial Interests, Institutional, Speaker’s Bureau, Received honoraria (all fees to institution): Takeda. A. Scherpereel: Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: AstraZeneca; Financial Interests, Personal, Advisory Role: Bristol Myers Squibb; Financial Interests, Personal, Speaker’s Bureau: Bristol Myers Squibb; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: Bristol Myers Squibb; Financial Interests, Institutional, Research Grant: Bristol Myers Squibb; Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: Roche; Financial Interests, Personal, Advisory Role: Merck Sharp & Dohme; Financial Interests, Personal, Speaker’s Bureau: Merck Sharp & Dohme; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: Merck Sharp & Dohme. R. Cornelissen: Financial Interests, Personal, Speaker’s Bureau: Roche; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Speaker’s Bureau: Pfizer; Financial Interests, Personal, Speaker’s Bureau: Bristol Myers Squibb; Financial Interests, Personal, Advisory Board: Merck Sharp & Dohme; Financial Interests, Personal, Advisory Board: Spectrum. Y. Oulkhouir: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb; Financial Interests, Personal, Advisory Board: Merck Sharp & Dohme; Financial Interests, Personal, Advisory Board: AstraZeneca. L. Greillier: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Bristol Myers Squibb; Financial Interests, Personal, Advisory Board: Boehringer Ingelheim; Financial Interests, Personal, Advisory Board: Merck Sharp & Dohme; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Takeda; Financial Interests, Personal, Advisory Board: AbbVie; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Novartis. T. Talbot: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb; Financial Interests, Personal, Other, Travel/expenses: Bristol Myers Squibb; Financial Interests, Personal, Speaker’s Bureau: Bristol Myers Squibb. I. Monnet: Non-Financial Interests, Personal, Invited Speaker, Congress: ESMO 2019: Pfizer; Non-Financial Interests, Personal, Invited Speaker, Congress: ESMO 2018: Roche. S. Hiret: Financial Interests, Personal and Institutional, Advisory Board: Takeda; Financial Interests, Personal and Institutional, Advisory Board: AstraZeneca. P. Baas: Financial Interests, Institutional, Advisory Role, Fee to hospital: Bristol Myers Squibb; Financial Interests, Institutional, Research Grant, Fee to hospital: Bristol Myers Squibb; Financial Interests, Institutional, Advisory Role, Fee to hospital: Takeda; Financial Interests, Institutional, Advisory Role, Fee to hospital: BeiGene; Financial Interests, Institutional, Advisory Role, Fee to hospital: AstraZeneca; Financial Interests, Institutional, Advisory Role, Fee to hospital: Merck Sharp & Dohme; Financial Interests, Institutional, Advisory Role, Fee to hospital: Roche; Financial Interests, Institutional, Advisory Role, Fee to hospital: Epizyme; Financial Interests, Institutional, Advisory Role, Fee to hospital: Trizell; Financial Interests, Institutional, Advisory Role, Fee to hospital: Daiichi Sankyo. A.K. Nowak: Financial Interests, Personal, Advisory Role, clinical trials consultant: Bayer; Financial Interests, Personal, Advisory Role, clinical trials consultant: Pharmabcine; Financial Interests, Personal, Advisory Role, clinical trials consultant: Trizell; Financial Interests, Personal, Advisory Board, clinical trial steering committee: Roche; Financial Interests, Personal, Advisory Board, clinical trial steering committee: Boehringer Ingelheim; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: Boehringer Ingelheim; Financial Interests, Personal, Advisory Board, clinical trial steering committee: Merck Sharp & Dohme; Financial Interests, Personal and Institutional, Advisory Role, clinical trials consultant: Douglas Pharmaceuticals; Financial Interests, Personal and Institutional, Research Grant: Douglas Pharmaceuticals; Financial Interests, Personal and Institutional, Advisory Role, clinical trials consultant: Atara Biotherapeutics; Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Institutional, Other, Travel/Accommodation/Expenses: AstraZeneca. N. Fujimoto: Financial Interests, Personal, Advisory Role: Ono Pharmaceutical; Financial Interests, Institutional, Research Grant: Ono Pharmaceutical; Financial Interests, Personal, Advisory Role: Bristol Myers Squibb. A.S. Tsao: Financial Interests, Institutional, Advisory Board: Genentech; Financial Interests, Personal, Advisory Board: Bristol Myers Squibb; Financial Interests, Personal, Advisory Board: Lilly; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Ariad; Financial Interests, Institutional, Advisory Board: EMD Serono; Financial Interests, Institutional, Research Grant: EMD Serono; Financial Interests, Institutional, Advisory Board: Merck; Financial Interests, Personal and Institutional, Advisory Board: Seattle Genetics; Financial Interests, Personal and Institutional, Research Grant: Seattle Genetics; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Boehringer Ingelheim; Financial Interests, Personal, Advisory Board: Sellas Life Science; Financial Interests, Personal, Advisory Board: Takeda; Financial Interests, Institutional, Research Grant: Millennium; Financial Interests, Institutional, Research Grant: Polaris; Financial Interests, Institutional, Research Grant: Epizyme. A.S. Mansfield: Financial Interests, Personal and Institutional, Advisory Role: AbbVie; Financial Interests, Personal and Institutional, Other, Travel/Accommodation/Expenses: AbbVie; Financial Interests, Institutional, Advisory Role: AstraZeneca; Financial Interests, Institutional, Advisory Role: Bristol Myers Squibb; Financial Interests, Institutional, Advisory Role: Genentech; Financial Interests, Institutional, Research Grant: Novartis; Financial Interests, Institutional, Research Grant: Verily; Financial Interests, Institutional, Member of the Board of Directors: Mesothelioma Applied Research Foundation; Financial Interests, Personal and Institutional, Other, Travel/Accommodation/Expenses: Roche; Financial Interests, Institutional, Advisory Role: Janssen; Financial Interests, Institutional, Research Grant: Mark Foundation; Financial Interests, Institutional, Research Grant: NIH. S. Popat: Financial Interests, Personal and Institutional, Advisory Board: Amgen; Financial Interests, Personal and Institutional, Research Grant: Amgen; Financial Interests, Personal and Institutional, Advisory Board: AstraZeneca; Financial Interests, Personal and Institutional, Principal Investigator: AstraZeneca; Financial Interests, Personal, Advisory Board: Bayer; Financial Interests, Personal, Advisory Board: Beigene; Financial Interests, Personal, Advisory Board: Blueprint; Financial Interests, Personal, Advisory Board: Bristol Myers Squibb; Financial Interests, Personal and Institutional, Principal Investigator: Boehringer Ingelheim; Financial Interests, Personal and Institutional, Advisory Board: Daiichi Sankyo; Financial Interests, Personal and Institutional, Principal Investigator: Daiichi Sankyo; Financial Interests, Personal, Advisory Board: Guardant Health; Financial Interests, Personal, Advisory Board: Janssen; Financial Interests, Personal, Advisory Board: Lilly; Financial Interests, Personal, Advisory Board: Merck KGaA; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal and Institutional, Advisory Board: Roche; Financial Interests, Personal and Institutional, Principal Investigator: Roche; Financial Interests, Personal and Institutional, Advisory Board: Takeda; Financial Interests, Personal and Institutional, Principal Investigator: Takeda; Financial Interests, Institutional, Principal Investigator: Ariad; Financial Interests, Institutional, Principal Investigator: Celgene; Financial Interests, Institutional, Principal Investigator: GlaxoSmithKline; Financial Interests, Institutional, Research Grant: Merck Sharp & Dohme; Financial Interests, Institutional, Principal Investigator: Trizel; Financial Interests, Institutional, Principal Investigator: Turing Point Therapeutics. X. Zhang: Financial Interests, Personal, Full or part-time Employment: Bristol Myers Squibb. N. Hu: Financial Interests, Personal, Full or part-time Employment: Bristol Myers Squibb. D. Balli: Financial Interests, Personal, Full or part-time Employment: Bristol Myers Squibb. J. Sanzari: Financial Interests, Personal, Full or part-time Employment: Bristol Myers Squibb. G. Zalcman: Financial Interests, Personal and Institutional, Advisory Role: AstraZeneca; Financial Interests, Personal and Institutional, Other, Travel/Accommodation/Expenses: AstraZeneca; Financial Interests, Personal and Institutional, Advisory Role: Bristol Myers Squibb; Financial Interests, Personal and Institutional, Other, Travel/Accommodation/Expenses: Bristol Myers Squibb; Financial Interests, Personal and Institutional, Advisory Role: Roche; Financial Interests, Personal and Institutional, Research Grant: Roche; Financial Interests, Personal and Institutional, Other, Travel/Accommodation/Expenses: Roche; Financial Interests, Personal, Advisory Role: Merck Sharp & Dohme; Financial Interests, Personal, Advisory Role: Da Volterra; Financial Interests, Personal and Institutional, Advisory Role: Inventiva; Financial Interests, Personal and Institutional, Research Grant: Inventiva; Financial Interests, Institutional, Other, Travel/Accommodation/Expenses: Boehringer Ingelheim; Financial Interests, Institutional, Other, Travel/Accommodation/Expenses: AbbVie; Financial Interests, Institutional, Other, Travel/Accommodation/Expenses: Pfizer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings